HeartFlow would like to take a moment to recognise sites that are going above and beyond to deliver an outstanding cardiac CT service to patients, especially during this COVID pandemic.
We are excited and proud to recognise the Royal Cornwall Hospitals NHS Trust for their Outstanding Cardiac CT Service!
In 2019, Cornwall experienced a surge in referrals for cardiac CT, as more centres across England adopted NICE’s CG95 CT-first guidelines. The team looked to tackle incremental efficiencies to increase scanning throughout by mapping out protocols and patient flows to ensure shorter lists and efficient patient visits. However, they continued to struggle with the sheer number of referrals coming through.
Then, as a key consultant went on planned maternity leave, Cornwall realised that they were going to have to decrease the number of cardiac CT lists per week. Cornwall realised they needed to increase staff flexibility to ensure they could maintain and expand their cardiac CT service, and combat the risk of lists being cancelled.
Cornwall drew up a solution to start running radiographer-led cardiac CT lists to increase the number of cardiac CT lists a week. During radiographer-led cardiac CT lists, radiographers were able to both oversee patient scans and administer appropriate beta blocking. Cardiac CT-trained consultants are not in the department when radiographer-led cardiac CT lists are run, making this a fully independent programme.
Today, the Royal Cornwall Hospital utilises a hybrid approach for their cardiac CT service – about half of the lists each week are radiographer led, while consultants supervise the other half. Consultants typically supervise lists with more complex patients based on referral details. Radiographer-led lists have allowed Cornwall to be nimble and flexible to reduce their outstanding cardiac CT patient lists even throughout the COVID pandemic.
Cornwall’s ability to be flexible, maximize resource utilization, and commitment to high quality cardiac CT is truly world class, and we, at HeartFlow, are so proud to be working with them to enhance heart care for their patients.
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.
Please apply for research grants through our online submission form.
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.